Targeted Protein Degradation: Clinical Advances in the Field of Oncology

The field of targeted protein degradation (TPD) is a rapidly developing therapeutic modality with the promise to tame disease-relevant proteins in ways that are difficult or impossible to tackle with other strategies. While we move into the third decade of TPD, multiple degrader drugs have entered t...

Full description

Saved in:

Bibliographic Details
Published in:	International journal of molecular sciences Vol. 23; no. 23; p. 15440
Main Authors:	Salama, Abdelrahman K A A, Trkulja, Marija V, Casanova, Emilio, Uras, Iris Z
Format:	Journal Article
Language:	English
Published:	Switzerland MDPI AG 06-12-2022 MDPI
Subjects:	Autophagy cancer Cancer therapies clinical trials CRISPR Degradation degrader molecules Disease Enzymes FDA approval Ligands Medical Oncology Monoclonal antibodies Multiple myeloma Phosphorylation Proteins Proteolysis Review targeted protein degradation Tumorigenesis Tumors targeted protein degradation cancer clinical trials degrader molecules
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	The field of targeted protein degradation (TPD) is a rapidly developing therapeutic modality with the promise to tame disease-relevant proteins in ways that are difficult or impossible to tackle with other strategies. While we move into the third decade of TPD, multiple degrader drugs have entered the stage of the clinic and many more are expected to follow. In this review, we provide an update on the most recent advances in the field of targeted degradation with insights into possible clinical implications for cancer prevention and treatment.
Bibliography:	ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-3 content type line 23 ObjectType-Review-1
ISSN:	1422-0067 1661-6596 1422-0067
DOI:	10.3390/ijms232315440